Contraception
Conditions
Keywords
contraception
Brief summary
To evaluate the effectiveness, device placement, safety, and tolerability of LevoCept to support commencing a Phase III Clinical Study
Detailed description
Study Design: Prospective, multi-center, single-arm, open-label, Phase II clinical study Approximately 250 subjects will be enrolled at about 14 centers in the US. Study Population: Pre-menopausal women ages 18 - 40, at risk for pregnancy, who are interested in using only this intrauterine contraceptive for birth control will be eligible for this study. Subjects must provide written informed consent and meet the study subject selection criteria without any exclusions as outlined in the Clinical Investigation Plan (CIP). Primary Effectiveness Outcome: The primary outcome measure is effectiveness, evaluated as the absence of pregnancy during LevoCept use. Safety and other outcome measures include: Study Device Placement: * Ease of placement * Placement success Safety: * Serious Adverse Events * Adverse Events Tolerability: * Bleeding and spotting patterns * Discontinuation rate and reasons for discontinuation
Interventions
DRUGLevoCept
placement of LevoCept IUD
Sponsors
Sebela Women's Health Inc.
Synteract, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
1. Between 18-40 years of age at the time of study initiation; 1.1 Enrollment will be targeted for 225 subjects aged 18-35 (for safety and effectiveness analyses) and an additional 25 subjects aged 36-40 (for safety only) (note: all subjects will be included in the analysis for device placement and tolerability); 2. Pre-menopausal, as determined by regular menstrual cycle (28 ± 7 days) for the last 3 months; 2.1 Based on patient history, when not on hormonal contraceptives; 3. Sexually active with a male partner who has not had a vasectomy; 4. Reasonably expected to have to coitus at least once monthly during the study period. 5. In a mutually monogamous relationship of at least 3-6 months duration; 6. Seeking to avoid pregnancy for the next 12 months; 7. Willing to use the study device as the sole form of contraception; 8. Willing to accept a risk of pregnancy; 9. Normal PAP or ASC-US with negative high risk HPV test result within the appropriate screen timeframe, and prior to LevoCept insertion; 10. Able and willing to comply with all study tests, procedures, assessment tools and follow-up; and 11. Able and willing to provide and document informed consent and Authorization for Release of Protected Health Information (PHI).
Exclusion criteria
1. Known or suspected pregnancy; or at risk for pregnancy from unprotected intercourse earlier in current cycle 2. Subject who anticipates separation from her partner for more than 1 cycle within the next 12 months; 3. A previously inserted IUD that has not been removed by the time LevoCept is placed; 4. History of previous IUD complications, such as perforation, expulsion, infection (pelvic inflammatory disease) or pregnancy with IUD in place.; 5. Injection of hormonal contraceptive (e.g., Depo-Provera) within the last 10 months; 5.1 Must have had 2 normal menstrual cycles since the last injection; 6. Planned use of any non-contraceptive estrogen, progesterone or testosterone any time during the 12 months of study participation; 7. Postpartum, prior to a minimum of 6 weeks and complete uterine involution; 8. Exclusively breastfeeding before return of menses; Lactating women will be excluded unless they have had two normal menstrual periods prior to enrollment. 8.1 Must have had 2 normal spontaneous menstrual cycles since delivery 9. Unexplained abnormal uterine bleeding (suspicious for serious condition), before evaluation; Immediately post-septic abortion or puerperal sepsis; 10. Severely heavy or painful menstrual bleeding; 11. Suspected or known cervical, uterine or ovarian cancer, or unresolved clinically significant abnormal pap smear requiring evaluation or treatment. 12. Any history of gestational trophoblastic disease with or without detectable elevated ß-hCG levels, or related malignant disease without an intervening normal pregnancy; 13. Any congenital or acquired uterine anomaly that may complicate IUD placement, such as: 13.1 Submucosal uterine leiomyoma 13.2 Asherman's syndrome 13.3 Pedunculated polyps 13.4 Bicornuate uterus 13.5 Didelphus or uterine septa 14. Any distortions of the uterine cavity (e.g. fibroids), in the opinion of the investigator, likely to cause issues during insertion, retention or removal of the IUD; 15. Known anatomical abnormalities of the cervix such as severe cervical stenosis, prior trachelectomy or extensive conization that, in the opinion of the investigator would prevent cervical dilation and study device placement; 16. Current or recent (within the last 3 months) untreated acute cervicitis or vaginitis; 17. Known or suspected breast cancer or other progestin-sensitive cancer now or in the past; 18. Known acute liver disease or liver tumor; 19. Subjects who have an established immunodeficiency; 20. High risk for STDs (e.g., multiple sexual partners); 21. Known or suspected HIV infection or clinical AIDS; 22. Known intolerance or allergy to any component of the LevoCept system; including nickel, silicone or tantalum; 23. Subject had LevoCept placed previously or had 2 attempts at placement; 24. Known or suspected alcohol or drug abuse within 12 months prior to the screening visit; 25. Any general health or behavioral condition that, in the opinion of the Investigator, could represent an increased risk for the subject or would render the subject less likely to provide the needed study information. 26. Subject is currently participating or has participated in another clinical study involving another investigational agent within 30 days of the planned LevoCept insertion date or is planning participation in another clinical trial with an investigational agent within 52 weeks (visit 6) after insertion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Contraceptive Efficacy Through During LevoCept Use | 1 Year, 2 Years, and 3 Years | Contraceptive efficacy through 3 years of use, as assessed by the Pearl Index. The Pearl Index is calculated as the number of on-treatment pregnancies per 100 woman-years of exposure. On-treatment pregnancy is defined as the estimated conception date being on or after the insertion date (must be a successful insertion) and no more than 7 days after the study drug is removed or expelled. One women year is defined as comprising thirteen 28-day cycles. A lower Pearl Index indicates greater contraceptive effectiveness. |
| Cumulative Pregnancy Percentage | Years 1-3 | A life table analysis (using Kaplan-Meier) of pregnancies will be performed for the EP population to present the cumulative pregnancy percentage |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| LevoCept Placement Success | Visit 1 (Day 1)/ LevoCept Placement | The number and percentage of subjects with either a successful or unsuccessful placement will be summarized |
| Ease of LevoCept Placement | Visit 1 (Day 1)/ LevoCept Placement | Ease of placement of the LevoCept was assessed by the clinician immediately following device placement. The clinician rated the ease of placement using the following options: "Very Easy," "Easy," "Neither Easy nor Hard," "Hard," or "Very Hard." This rating was based on the clinician's experience during the placement procedure. |
| Bleeding and Spotting Patterns (Number of Bleeding and/or Spotting Days Per Cycle) | Cycle 1 to Cycle 13 (post IUD placement). Each cycle is 28 days. | Bleeding and spotting patterns will be summarized for the first year of treatment (Cycle 1 to Cycle 13) by the mean number of days in each 28-day cycle with bleeding or spotting and spotting only |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORDavid Turok, MD
University of Utah
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 27.8 years STANDARD_DEVIATION 5.16 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 47 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 232 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants |
| Race (NIH/OMB) Asian | 15 Participants |
| Race (NIH/OMB) Black or African American | 57 Participants |
| Race (NIH/OMB) More than one race | 15 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants |
| Race (NIH/OMB) White | 188 Participants |
| Sex: Female, Male Female | 279 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 279 |
| other Total, other adverse events | 264 / 279 |
| serious Total, serious adverse events | 4 / 279 |
Outcome results
None listed